Featured content
Targeting SRC-3 to reprogramme regulatory T cells in cancer
Could targeting SRC-3 in regulatory T cells help overcome tumour immunosuppression? Researchers explain how this approach could restore anti-tumour immunity and what remains to be proven in patients.
ArticleThe next gene-editing breakthrough may start with the donor template
The editing machinery gets much of the attention in genome editing, but it’s the donor DNA template that can determine whether an edit works. Long synthetic ssDNA could offer researchers another option.
ArticleScientists are already using AI agents. Most of what they learn goes unpublished.
Dr Raminderpal Singh speaks to Dr Srijit Seal about how AI agents are changing computational drug discovery, the impact on scientists’ daily work and why valuable findings remain unpublished.
ArticleWhat will it take to trust human-relevant models in drug discovery?
Could organ-on-a-chip technology help identify drug failures before clinical trials? Jim Corbett of Emulate discusses the evidence needed to make human-relevant models reliable tools in drug discovery.
News
NewsDual-therapy approach targets TNBC energy supply in preclinical study
A combination of a CD276-targeting antibody-drug conjugate and mitochondria-disrupting gene therapy has demonstrated anti-tumour activity in preclinical models of metastatic triple-negative breast cancer.
NewsImmune profiling could help tailor treatment for primary biliary cholangitis
A new review of primary biliary cholangitis reveals how interactions between bile duct epithelial cells and immune populations sustain chronic inflammation, and explores whether mapping individual disease mechanisms could guide more targeted therapies.
NewsHidden bacterial compounds reveal potential cancer drug leads
Researchers have discovered a new family of bacterial natural products that bind the cancer-associated enzyme AKR1C3, revealing potential starting points for drug discovery.
NewsWhy aptamer cancer therapies are struggling to reach the clinic
Aptamers can recognise cancer-associated targets and deliver drugs directly to tumour cells. So why have so few reached the clinic? A new review examines the barriers to their development.
From our partners
Webinar
From vial to viable: best practices for culturing organoids
Poor recovery, inconsistent growth and changes in morphology can affect organoid research. How much experimental variability starts with the culture itself?
Webinar
Virus-like particles for vaccine serology: from dengue VLP production to neutralising antibody detection
Find out how virus-like particles are produced at scale, and how they can be used to measure IgM, IgG and neutralising antibody responses in vaccine development.
Opinion and interviews
A sceptical guide to AI agents in drug discovery
AI agents promise to transform drug discovery, but where do they really add value? Dr Eric Ma examines search, model choice, vendor lock-in and why scientific expertise matters more than ever.
- Previous
- Next
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
Upcoming Webinars
Webinar
Spatial proteomics in FFPE tumour tissue: an end-to-end workflow from prostate cancer research
Follow a complete high-plex spatial proteomics workflow on archival FFPE tumour tissue, from marker-panel design to cell phenotyping, with a prostate cancer case study from the University of Surrey.
Webinar
Cracking cell dynamics with single-cell proteomics and CRISPR
What can pooled CRISPR screening and protein‑level readouts reveal that transcriptomics alone can’t? Explore how single‑cell genomic perturbations, intracellular protein measurements and surface‑protein profiling expose signalling pathways and clarify antibody specificity.
Webinar
What it really takes to turn cancer discoveries into new therapies
Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.
Webinar
Virus-like particles for vaccine serology: from dengue VLP production to neutralising antibody detection
Find out how virus-like particles are produced at scale, and how they can be used to measure IgM, IgG and neutralising antibody responses in vaccine development.
Webinar
From vial to viable: best practices for culturing organoids
Poor recovery, inconsistent growth and changes in morphology can affect organoid research. How much experimental variability starts with the culture itself?
Spatial proteomics in FFPE tumour tissue: an end-to-end workflow from prostate cancer research
Cracking cell dynamics with single-cell proteomics and CRISPR
What it really takes to turn cancer discoveries into new therapies
Virus-like particles for vaccine serology: from dengue VLP production to neutralising antibody detection
From vial to viable: best practices for culturing organoids
On-demand Webinars
- Previous
- Next
